CLEAN Clean Science and Technology Q3 FY26 results (Oct–Dec 2025) and concall
Clean Science reported a challenging Q3 FY26 with consolidated revenue moderating to ₹216 crores, a 10% sequential decline, and a 21% YoY decline in sales primarily due to volume softness and pricing pressure. Consolidated EBITDA and PAT margins stood at 33% and 21% respectively. Despite headwinds from Chinese competition and tariffs, the HALS business showed strong 55% YoY growth and achieved EBITDA breakeven in its subsidiary. The company is focused on operational discipline, new product commercialization, and maintaining market share amidst evolving market conditions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 8.7%, net profit down 30.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 238 | 241 | 264 | 243 | 245 +3% | 220 −9% |
| EBITDA | 90 | 98 | 105 | 100 | 87 −3% | 72 −27% |
| Net profit | 59 | 66 | 74 | 70 | 55 −7% | 46 −30% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
